Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.
Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
The 340B program has had a great impact on access to HIV treatment and prevention services in the US.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
More treatment options and modalities are now available for patients.
This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.
Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.
George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Ongoing education and proven outcomes need to aid this form of testing.
This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
Imprecise language can fuel infodemics and misinformation and damage public trust.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.